^Mascias, P; Scheede, M; Bloms-Funke, P; Chizh, B (2002). "Modulation of spinal nociception by GluR5 kainate receptor ligands in acute and hyperalgesic states and the role of gabaergic mechanisms". Neuropharmacology. 43 (3): 327–39.
doi:
10.1016/S0028-3908(02)00112-0.
PMID12243762.
S2CID29126134.
^Alt, A; Weiss, B; Ogden, AM; Knauss, JL; Oler, J; Ho, K; Large, TH; Bleakman, D (2004). "Pharmacological characterization of glutamatergic agonists and antagonists at recombinant human homomeric and heteromeric kainate receptors in vitro". Neuropharmacology. 46 (6): 793–806.
doi:
10.1016/j.neuropharm.2003.11.026.
PMID15033339.
S2CID23514969.
^Mascias, P; Scheede, M; Bloms-Funke, P; Chizh, B (2002). "Modulation of spinal nociception by GluR5 kainate receptor ligands in acute and hyperalgesic states and the role of gabaergic mechanisms". Neuropharmacology. 43 (3): 327–39.
doi:
10.1016/S0028-3908(02)00112-0.
PMID12243762.
S2CID29126134.
^Alt, A; Weiss, B; Ogden, AM; Knauss, JL; Oler, J; Ho, K; Large, TH; Bleakman, D (2004). "Pharmacological characterization of glutamatergic agonists and antagonists at recombinant human homomeric and heteromeric kainate receptors in vitro". Neuropharmacology. 46 (6): 793–806.
doi:
10.1016/j.neuropharm.2003.11.026.
PMID15033339.
S2CID23514969.